Phreesia (PHR) Q2 2027 Earnings Call Transcript
Phreesia (PHR) reported Q2 2027 revenue of $129.5M, up 10% YoY, with adjusted EBITDA of $32.9M and net income of $1.9M. AHSCs grew 6% to 4,744. Full-year guidance: revenue $510M-$520M, adjusted EBITDA $125M-$135M. Management noted variability in revenue forecasting and economic pressures on healthcare providers.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance indicate operational momentum and may attract growth‑oriented investors.
Market read
First‑report earnings with upgraded guidance provide a fresh trading catalyst for PHR.
What to watch
Potential headwinds from payer strain and variability in network solutions revenue.
Background
Phreesia is a patient engagement and payment platform serving healthcare providers.
Ticker impact
Phreesia reported Q2 FY2027 results with revenue of $129.5M (+10% YoY) and raised full-year revenue guidance to $510M-$520M.
Potential price appreciation in the next trading session as investors digest the beat and upgraded outlook.
Earnings beat, higher guidance, and cash generation provide a clear catalyst for buying pressure.
Market effects
Positive earnings may lift other health‑tech and patient‑engagement platforms.
U.S. healthcare technology sector could see modest gains.
Limited to U.S. markets; no direct global ripple.
Counterpoint
If the guidance is overly optimistic, the stock could face a pull‑back on later detailed guidance.
Key entities
- ExecutiveBalaji Gandhi
Chief Financial Officer who presented the financial results.
- ExecutiveChaim Indig
Chief Executive Officer who discussed strategic initiatives.
